Next, to identify BRCA1-downregulating compounds that cooperate with PARPi in breast cancer cells, the 35 candidate drugs were tested for their capacity to sensitize MDA-MB-231 cells to olaparib. This evidence concerns the gene BRCA1 and breast carcinoma.